177 related articles for article (PubMed ID: 36314696)
21. Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin Cancer.
Chen L; Aria AB; Silapunt S; Migden MR
Dermatol Surg; 2019 Jan; 45(1):1-16. PubMed ID: 30045105
[TBL] [Abstract][Full Text] [Related]
22. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment.
Stratigos AJ; Garbe C; Dessinioti C; Lebbe C; Bataille V; Bastholt L; Dreno B; Concetta Fargnoli M; Forsea AM; Frenard C; Harwood CA; Hauschild A; Hoeller C; Kandolf-Sekulovic L; Kaufmann R; Kelleners-Smeets NWJ; Malvehy J; Del Marmol V; Middleton MR; Moreno-Ramirez D; Pellecani G; Peris K; Saiag P; van den Beuken-van Everdingen MHJ; Vieira R; Zalaudek I; Eggermont AMM; Grob JJ;
Eur J Cancer; 2020 Mar; 128():83-102. PubMed ID: 32113942
[TBL] [Abstract][Full Text] [Related]
23. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.
Ahmed SR; Petersen E; Patel R; Migden MR
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):947-951. PubMed ID: 31524530
[No Abstract] [Full Text] [Related]
24. Treatment of advanced cutaneous squamous cell carcinoma: a Mohs surgery and dermatologic oncology perspective.
Wilmas KM; Nguyen QB; Patel J; Silapunt S; Migden MR
Future Oncol; 2021 Dec; 17(35):4971-4982. PubMed ID: 34608809
[TBL] [Abstract][Full Text] [Related]
25. New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma.
Villani A; Potestio L; Fabbrocini G; Scalvenzi M
Adv Ther; 2022 Mar; 39(3):1164-1178. PubMed ID: 35089534
[TBL] [Abstract][Full Text] [Related]
26. Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment.
Gambale E; Fancelli S; Caliman E; Petrella MC; Doni L; Pillozzi S; Antonuzzo L
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101944
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges.
Ansary TM; Hossain MDR; Komine M; Ohtsuki M
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955666
[TBL] [Abstract][Full Text] [Related]
28. Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma.
Zhao CY; Hwang SJE; Anforth R; Carlos G; Chou S; Carlino M; Fernández-Peñas P
J Immunother; 2018 Sep; 41(7):343-349. PubMed ID: 29939876
[TBL] [Abstract][Full Text] [Related]
29. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
[TBL] [Abstract][Full Text] [Related]
30. Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study).
Ishii M; Hirai I; Tanese K; Fusumae T; Nakamura Y; Fukuda K; Uchi H; Kabashima K; Otsuka A; Yokota K; Yamazaki N; Namikawa K; Fujimura T; Takenouchi T; Yamamoto Y; Nishiguchi M; Sato Y; Amagai M; Funakoshi T
Medicine (Baltimore); 2020 Oct; 99(44):e22913. PubMed ID: 33126349
[TBL] [Abstract][Full Text] [Related]
31. Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review.
Choi FD; Kraus CN; Elsensohn AN; Carley SK; Lehmer LM; Nguyen RT; Linden KG; Shiu J
J Am Acad Dermatol; 2020 Feb; 82(2):440-459. PubMed ID: 31163235
[TBL] [Abstract][Full Text] [Related]
32. Mohs surgery is effective for high-risk cutaneous squamous cell carcinoma.
Pugliano-Mauro M; Goldman G
Dermatol Surg; 2010 Oct; 36(10):1544-53. PubMed ID: 21053415
[TBL] [Abstract][Full Text] [Related]
33. Novel treatments using PD1 inhibitors for advanced and metastatic cutaneous squamous cell carcinoma.
Pezeshki S; Hemmati S; Rezaei N
Expert Rev Anticancer Ther; 2020 Oct; 20(10):819-822. PubMed ID: 32852235
[No Abstract] [Full Text] [Related]
34. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
[TBL] [Abstract][Full Text] [Related]
35. [Locally advanced and metastatic cutaneous squamous cell carcinoma treated with cemiplimab].
Vanhakendover L; Lebas E; Libon F; Wauters O; Dezfoulian B; Marchal N; Rorive A; Piret P; Quatresooz P; Jacquemin D; Nikkels AF
Rev Med Liege; 2019 Jul; 74(7-8):436-440. PubMed ID: 31373461
[TBL] [Abstract][Full Text] [Related]
36. Incidence of invasive squamous cell carcinomas in biopsy-proven squamous cell carcinomas in situ sent for Mohs micrographic surgery.
Chuang GS; Lu LK; Cummins DL; Wu H; Finn D; Rogers GS; Lee D
Dermatol Surg; 2012 Sep; 38(9):1456-60. PubMed ID: 22734860
[TBL] [Abstract][Full Text] [Related]
37. Pattern of response of unresectable and metastatic cutaneous squamous cell carcinoma to programmed death-1 inhibitors: A review of the literature.
Corneli P; Conforti C; Retrosi C; Vezzoni R; di Meo N; Piccolo V; Farinazzo E; Russo T; Magaton Rizzi G; Giuffrida R; Zalaudek I
Dermatol Ther; 2020 Mar; 33(2):e13250. PubMed ID: 32022968
[TBL] [Abstract][Full Text] [Related]
38. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
Benzaquen M
Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547
[TBL] [Abstract][Full Text] [Related]
39. Squamous cell carcinoma developing within lichen planus of the penis. Treatment with Mohs micrographic surgery.
Leal-Khouri S; Hruza GJ
J Dermatol Surg Oncol; 1994 Apr; 20(4):272-6. PubMed ID: 8163749
[TBL] [Abstract][Full Text] [Related]
40. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
Tillman DK; Carroll MT
Cutis; 2007 Mar; 79(3):241-8. PubMed ID: 17674590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
